Teva Pharmaceutical Industries Ltd $ 11.76 0.15 (1.29%)

Avg Vol (1m):
Market Cap $:
12.51 Bil
Enterprise Value $:
38.44 Bil
P/E (TTM):
Warning! GuruFocus has detected 3 Severe warning signs with TEVA. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

TEVA News and Headlines - Teva Pharmaceutical Industries

GuruFocus Articles Total 225
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 12

Shares of JetBlue Airways and Teva Pharmaceuticals jump strong on earnings

Shares of JetBlue Airways Corp. (JBLU) gained more than 2% on Thursday after the company posted first-quarter results. Revenue declined 15% from the prior-year quarter to $1.59 billion, falling $40 million short of expectations. The company posted a loss of 42 cents per share, beating estimates by 1 cent.

“We entered this crisis with the second strongest balance sheet among U.S. airlines," CEO Robin Hayes said. "In the past two months, we have moved quickly to both protect and strengthen our liquidity position. Since the beginning of March, we have made decisive changes to our growth plan to minimize cash

106 Views    Omar Venerio    2020-05-07 20:33
Fund's largest sales of the 1st quarter

The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2020.

CVS Health

The fund exited its CVS Health Corp. (CVS) stake. The portfolio was impacted by -1.82%.


The health care services provider has a market cap of $77.59 billion and an enterprise value of $158.84 billion

GuruFocus gives the company a profitability rating of 8 out of 10. The return on equity of 10.85% and return on assets of 3.08% are underperforming 78% of companies in the health care plans industry. Its financial

224 Views    Tiziano Frateschi    2020-05-05 19:50
Fund sells CVS, invests in a new IPO

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the first quarter of 2020, which ended on March 31.

Founded in 1984, the fund has been investing globally in health care-related stocks with the aim of long-term capital appreciation for over 30 years. Portfolio manager Jean Hynes, who has been advising the fund since 2008, chooses stocks based primarily on balance sheet strength, good management teams and product pipelines that show high potential for consistent profitability and growth.

At the end of the quarter, the fund consisted of holdings in 89 stocks valued

387 Views    Margaret Moran    2020-05-01 19:55
Pricing is increasing for makers of copycat medicines

At least one analyst is predicting Covid-19 could be beneficial to generic drug companies as concerns over the supply chain ease, according to an article in FiercePharma. In fact, prices for generic drugs are increasing, meaning the coronavirus pandemic could boost profits for the makers of copycat medicines.

Early concerns that there would be shortages in the worldwide supply have diminished. In a Wednesday note to investors, Bernstein analyst Ronny Gal said the global generic drug supply is likely to come back strong and record solid growth, although “spot shortages” could still occur.

This would be a welcome development

376 Views    Barry Cohen    2020-03-27 21:45
Company has cut $3 billion in expenses and has high hopes for two key drugs

Teva Pharmaceutical Industries Ltd. (TEVA) has cleared the decks, and the company is signaling full speed ahead.

That was the message conveyed to analysts during the company’s year-end earnings call on Feb. 12. A multiyear restructuring by the Israeli company is going to save about $3 billion in yearly expenses. That’s the tally after Teva shed about 13,000 employees, shuttered 13 manufacturing plants—with 10 more to go--and closed 40 offices and laboratories.

Now leaner and more agile, the company is banking heavily on two of its key products to drive growth, the migraine medication Ajovy and Austedo, a treatment for

192 Views    Barry Cohen    2020-02-13 19:42
Optimism surrounds these companies’ launch of drugs in 2020

Of the ten most anticipated drug launches expected this year, two will have the biggest impact on the top line—and possibly the share price--of the companies introducing them.

Aimmune Therapeutics

Heading the list of biggest potential beneficiaries is Aimmune Therapeutics, Inc. (AIMT), whose new drug Palforzia is expected to generate nearly $1.3 billion in sales by 2024. This is a significant development considering that this San Francisco-based biotech has never had a major source of sales revenue.

Palforzia is a food allergy treatment, a field most pharmaceutical companies steer clear of. The drug is a

322 Views    Barry Cohen    2020-02-04 15:22
Guru invests in Canadian bank and an Austrian paper manufacturer

Polaris Capital Management’s Bernard Horn (Trades, Portfolio) released his third-quarter portfolio last week, revealing he established two new positions and exited two others.

With the goal of capital appreciation and strong risk-adjusted returns, the guru’s Boston-based firm invests in discounted but high-quality stocks in developed as well as emerging markets.

Based on these criteria, the guru opened positions in The Toronto-Dominion Bank (TSX:TD) and Mondi PLC (LSE:MNDI) during the quarter. He also exited his Standard Chartered PLC (LSE:STAN) and Teva Pharmaceutical Industries Ltd. (TEVA) holdings.

Toronto-Dominion Bank

Horn invested in 102,800 shares of Toronto-Dominion, allocating 1.39% of

182 Views    Sydnee Gatewood    2019-12-10 15:41
The companies both hit the dubious roster twice, but are joined by many of the biggest names in the drug industry

In a late October article, Bayer (XTER:BAYN) was credited with making one of the worst corporate deals ever with its acquisition of Monsanto. Now, FierceBiotech has published a list of the worst 15 corporate buys over the past 10 years, with Bayer and Teva (TEVA) cited twice.

Biopharma companies have spent hundreds of billions of dollars on mergers and acquisitions over the last decade that changed the face of the drug industry and resulted in large layoffs, facilities being shut down, research and development programs being stopped and (for some companies) a burdensome pile of debt.

That’s not to say

300 Views    Barry Cohen    2019-12-04 22:52
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise

The growing number of bankruptcies among biotech companies should send shudders through investors. And a number of companies, some with prominent names, could be joining this dubious list of business failures.

A Nov. 19 article in BioPharma Dive reported that 11 biotech companies have declared bankruptcy this year. That's nearly three times the average number who sought the shield in the past 10 years, according to the firm Bankruptcy Data.

The highest-profile filing was not by a biotech, but by pain management company Purdue Pharma, which was hit with a wave of lawsuits for its role in fueling

482 Views    Barry Cohen    2019-11-19 21:54
Anthem tops the list

The Vanguard Health Care Fund (Trades, Portfolio), which invests at least 80% of its assets in stocks of companies principally related to the health care industry, bought shares of the following stocks in both the second and third quarters.

Anthem Inc. (ANTM)

The fund increased its position by 17.36% in the second quarter and then raised it by 4.17% in the third quarter. The stock has a weight of 2.45% in the portfolio.


The American managed-care organization has a market cap of $68.90 billion. Its revenue of $100.17 billion has grown

200 Views    Tiziano Frateschi    2019-11-07 19:30
Bausch Health Companies tops the list

According to the GuruFocus All-In-One Screener as of Tuesday, the following health care stocks are popular among gurus.

Masimo Corp. (MASI) is held by six gurus

The Irvine, California-based medical device company has a market cap of $7.63 billion. Its revenue of $895 million has risen 11.90% over a 10-year period.


The stock is trading with a price-book ratio of 7.50. The share price of $149 is 8.51% below the 52-week high and 49.25% above the 52-week low. Over the last 10 years, it has returned 461.29%.

The company’s largest guru shareholder is

172 Views    Tiziano Frateschi    2019-10-01 18:50
Discussion of markets and holdings



August 20, 2019

Dear Unitholders of Chou Europe Fund,

The net asset value per unit (“NAVPU”) of a Series A unit of Chou Europe Fund at June 30, 2019 was $8.44 compared to $9.06 at December 31, 2018, an decrease of 6.8%; during the same period, the MSCI AC (Morgan Stanley Capital International All Country) Europe Total Return Index in Canadian dollars increased 12.0%. In U.S. dollars, a Series A unit of Chou Europe Fund was down 2.9% while the MSCI AC Europe Total Return Index increased 16.6%.

The table shows our one-year, three-year, five-year and

89 Views    Holly LaFon    2019-09-11 19:06
Looking at the dogs in Berkshire's portfolio

The performance of Berkshire Hathaway's (BRK.A) (BRK.B) equity portfolio this year has been a mixed bag.

On one hand, Warren Buffett (Trades, Portfolio)'s favorite investment, Apple Inc. (AAPL), which made up just under 40% of Berkshire's equity portfolio at the end of the second quarter, has returned 35% so far this year. The stock has substantially outperformed the S&P 500, which has returned 18.7% year to date at the time of writing.

On the other hand, a handful of stocks have underperformed the market, costing the "Oracle of Omaha" several billion dollars so far this year. While

752 Views    Rupert Hargreaves    2019-09-06 22:18
Shares of the world’s biggest generic drug company have been pummeled, but there are some bright spots

Shareholders of Teva Pharmaceutical Industries Ltd. (TEVA) are searching for any reasons to be optimistic that the battered, bruised and beaten-down generic drugmaker can emerge from the depths of despair.

In just over four years, the Israel-based company has lost 90% of its market value and currently trades at about $7. Beleaguered investors can take some consolation in the fact they’re in good company: Two of the largest owners of Teva stock are Warren Buffett (Trades, Portfolio)’s Berkshire Hathaway (BRK.A)(BRK.B) and Capital Group Companies, one of the world’s biggest investment houses.

While Buffett has

486 Views    Barry Cohen    2019-09-06 14:22
Bayer has lost nearly the entire value of its 2018 Monsanto purchase. Teva has already lost more than the entire value of its Actavis Generics purchase. Did antitrust regulators see that coming?

One of the world’s largest and oldest pharmaceutical companies buys out one of the world’s largest agriculture firms, and the stock collapses in freefall. One would think this to be impossible. Should such formidable combination of market power lead to even more power?

Since closing the Monsanto deal in June 2018 until it hit recent lows last May, Bayer AG (OTCQB:BAYRY) had lost as much as 47 billion euros in market cap. The euro back then was at $1.17. It is now at $1.10. That means that from the time of the deal closing to its May lows, Bayer lost

173 Views    Matt Winkler    2019-09-03 14:04
Buying Teva on the assumption that it is now a takeover target is risky. Here's why

Now that Pfizer (PFE)'s Upjohn and Mylan (MYL) are combining in a new spinoff, it looks like Teva (TEVA) could be next. Judging by price movements in Teva since Pfizer made its move, some traders may be anticipating this. The stock is up nearly 7% since the deal was announced.

But buying Teva on the assumption of it being acquired is more risky than it looks, even at these levels. Here’s why.

First, it can hardly be said that Pfizer and Mylan joining forces is good for Teva in any fundamental sense. The new company will have a healthier balance

350 Views    Matt Winkler    2019-08-02 16:09
Four stock ideas were pitched during the month. Enter your idea today

With the arrival of August, the Value Idea Contest enters its 11th month.

In July, contestants submitted three new ideas, bringing the total entered in the contest to 44. If any of these stocks doubles within 12 months after the publication date, the author will win $1,000. Read all of the contest submissions here. Here are the ideas for July 2019.

254 Views    Holly LaFon    2019-07-31 21:59
Should you follow the footsteps of Berkshire's protégées in this case?

I have had Teva (TEVA), an Israel-based drugmaker, on my stock watchlist for a long time. Many investors and financial analysts regard it as a sinking ship. That makes it a security worth analyzing.

Company history

Teva Pharmaceutical Industries Ltd. is a multinational pharma company -- the largest generic drug manufacturer in the world. Through its history, it grew by intense mergers and acquisitions. The company, as known today, was incorporated in 1944.

Now, Teva is a struggling business due to a miscalculated acquisition of Allergan's generic subsidiary, Actavis Generics, at a high figure of $40.5 billion.

In hindsight,

802 Views    Matthew Sipos    2019-07-29 15:21
Guru stock highlight

Double-digit gains from Quest Diagnostics and Allergan PLC helped temper losses in health care, which were entirely attributable to Teva Pharmaceutical (TEVA). The Israeli-based generic drug manufacturer faced multiple legal battles. The Connecticut Attorney General led more than 40 states in a 500+ page lawsuit against Teva and competitors for generic drug price fixing. A separate generic price fixing criminal investigation may be filed by the Justice Department. Furthermore, Teva settled one of its outstanding opioid lawsuits with Oklahoma for $85 million. Investors extrapolated this settlement figure to other pending opioid lawsuits; Teva management refuted this calculation. Nevertheless, the

1370 Views    Holly LaFon    2019-07-18 20:19
Nintai's purchase of Allergan provides us with a case study on deciding what's more important: ethics or profit

Some companies can make millionaires out of their shareholders without a shred of moral character. However, we would argue that few of these shareholders have been long-term value investors. Management without character is like ice cream on a hot afternoon – delicious while it lasts but it always ends up leaving you in an awful sticky mess.” - Henry Acton

"It's a story about the delinquent society—and I use that phrase intentionally—that grew up around the company, and here I'm referring to the collusion of Enron's various advisors and financial intermediaries. And most importantly, Enron is a story about

679 Views    Thomas Macpherson    2019-06-26 19:18

Headlines Total 182
  • 1
  • 2

2020-07-09 $ 11.61 (1.84%)
2020-07-08 $ 11.4 (1.69%)
2020-07-07 $ 11.21 (-2.69%)
2020-07-03 $ 11.35 (%)
2020-07-02 $ 11.35 (-1.39%)
2020-07-01 $ 11.51 (-6.65%)
2020-06-23 $ 12.91 (-0.84%)
2020-06-22 $ 13.02 (2.76%)
2020-06-19 $ 12.67 (3.01%)
2020-06-18 $ 12.3 (2.16%)
2020-06-16 $ 12.07 (4.96%)
2020-06-15 $ 11.5 (2.22%)
2020-06-12 $ 11.25 (-0.71%)
2020-06-09 $ 12.63 (-1.94%)
2020-06-08 $ 12.88 (0.31%)
2020-06-03 $ 12.88 (-1.08%)
2020-05-29 $ 12.53 (-3.02%)
2020-05-27 $ 12.91 (4.79%)
2020-05-26 $ 12.32 (3.01%)
2020-05-22 $ 11.96 (-0.5%)
2020-05-21 $ 12.02 (0.17%)
2020-05-20 $ 12 (-0.08%)
2020-05-15 $ 11.21 (2.19%)
2020-05-13 $ 11.05 (-3.24%)
2020-05-12 $ 11.42 (-0.26%)
2020-05-08 $ 11.29 (-2.25%)
2020-05-07 $ 11.55 (10.21%)
2020-05-05 $ 10.09 (2.85%)
2020-05-04 $ 9.81 (-3.25%)
2020-04-30 $ 10.74 (-2.98%)
2020-04-29 $ 11.07 (2.12%)
2020-04-28 $ 10.84 (1.12%)
2020-04-27 $ 10.72 (4.89%)
2020-04-24 $ 10.22 (0.39%)
2020-04-23 $ 10.18 (3.46%)
2020-04-17 $ 10.27 (-0.87%)
2020-04-13 $ 10.33 (1.67%)
2020-04-07 $ 9.54 (0.85%)
2020-04-02 $ 8.12 (-4.13%)
2020-03-31 $ 8.98 (5.52%)
2020-03-30 $ 8.51 (12.57%)
2020-03-27 $ 7.56 (-4.3%)
2020-03-26 $ 7.9 (0.77%)
2020-03-25 $ 7.84 (-3.45%)
2020-02-13 $ 12.57 (-6.54%)
2020-01-29 $ 10.38 (1.67%)
2019-11-19 $ 10.29 (-0.48%)
2019-11-14 $ 9.37 (-4.19%)
2019-11-07 $ 8.47 (4.57%)
2019-10-01 $ 6.76 (-1.74%)
2019-09-06 $ 7.01 (1.74%)
2019-08-20 $ 7.01 (4.47%)
2019-08-19 $ 6.71 (4.68%)
2019-08-16 $ 6.41 (4.06%)
2019-08-13 $ 7.04 (0.28%)
2019-08-08 $ 7.29 (3.26%)
2019-08-05 $ 7.83 (-0.38%)
2019-08-02 $ 7.86 (0.38%)
2019-07-30 $ 7.91 (0.64%)
2019-07-29 $ 7.86 (4.24%)
2019-07-25 $ 7.6 (-5%)
2019-07-23 $ 7.68 (-0.13%)
2019-07-22 $ 7.69 (-2.78%)
2019-07-18 $ 7.83 (-3.45%)
2019-07-16 $ 8.2 (-4.21%)
2019-07-12 $ 9.25 (3.12%)
2019-07-09 $ 9.37 (2.18%)
2019-07-05 $ 9.47 (-1.35%)
2019-07-02 $ 9.43 (1.18%)
Total 182
  • 1
  • 2